GSA Capital Partners LLP Buys New Stake in Ultragenyx Pharmaceutical Inc. $RARE

GSA Capital Partners LLP purchased a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 22,723 shares of the biopharmaceutical company’s stock, valued at approximately $684,000.

A number of other institutional investors have also modified their holdings of the stock. Norges Bank purchased a new position in Ultragenyx Pharmaceutical during the second quarter valued at approximately $35,765,000. Hsbc Holdings PLC grew its stake in shares of Ultragenyx Pharmaceutical by 88.6% during the 2nd quarter. Hsbc Holdings PLC now owns 97,197 shares of the biopharmaceutical company’s stock worth $3,554,000 after purchasing an additional 45,665 shares during the period. Skandinaviska Enskilda Banken AB publ increased its holdings in shares of Ultragenyx Pharmaceutical by 108.1% during the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 67,720 shares of the biopharmaceutical company’s stock valued at $2,462,000 after purchasing an additional 35,185 shares in the last quarter. Frazier Life Sciences Management L.P. lifted its stake in shares of Ultragenyx Pharmaceutical by 49.3% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 983,715 shares of the biopharmaceutical company’s stock valued at $35,768,000 after purchasing an additional 325,000 shares during the period. Finally, Schroder Investment Management Group lifted its stake in shares of Ultragenyx Pharmaceutical by 27.2% in the 2nd quarter. Schroder Investment Management Group now owns 336,173 shares of the biopharmaceutical company’s stock valued at $12,223,000 after purchasing an additional 71,888 shares during the period. Hedge funds and other institutional investors own 97.67% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on RARE shares. Wedbush restated a “neutral” rating and set a $25.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, February 17th. Leerink Partners lowered their price objective on Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Tuesday, December 30th. Guggenheim cut their price objective on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a “buy” rating for the company in a research note on Monday, January 5th. Truist Financial decreased their target price on Ultragenyx Pharmaceutical from $100.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Finally, HC Wainwright dropped their price target on Ultragenyx Pharmaceutical from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, February 17th. Sixteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $68.29.

Ultragenyx Pharmaceutical Stock Up 4.1%

NASDAQ:RARE opened at $22.72 on Monday. Ultragenyx Pharmaceutical Inc. has a 52 week low of $18.41 and a 52 week high of $45.00. The stock’s fifty day moving average is $25.40 and its two-hundred day moving average is $29.52. The company has a market capitalization of $2.20 billion, a P/E ratio of -3.89 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 85.54%.The business had revenue of $207.28 million for the quarter, compared to analyst estimates of $199.60 million. During the same period in the previous year, the business posted ($1.39) earnings per share. The firm’s revenue for the quarter was up 25.5% compared to the same quarter last year. Sell-side analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Analyst support and updated estimates: HC Wainwright reiterated a Buy and updated / raised multi‑quarter and FY‑2027 EPS forecasts, keeping a $50 target — a positive signal for future earnings trajectory and investor sentiment. HC Wainwright price target and estimates
• Positive Sentiment: Inducement RSU grants to new hires: Ultragenyx granted 22,917 restricted stock units to six newly hired non‑executive officers (vesting over four years) under its Employment Inducement Plan — indicates investment in talent for development/commercialization execution. Ultragenyx Reports Inducement Grant
• Neutral Sentiment: Mixed sell‑side views: Wedbush reiterated a Neutral rating while other outlets published a range of analyst price targets (median cited around $55) — keeps the stock in focus but provides no clear directional catalyst by itself. Wedbush reiterates Neutral
• Negative Sentiment: Ongoing securities‑class action notices and lead‑plaintiff deadlines: Multiple firms (Kessler Topaz, Schall, Faruqi, Pomerantz, Robbins Geller, Levi & Korsinsky, Rosen, etc.) are soliciting Ultragenyx investors in a suit covering Aug 3, 2023–Dec 26, 2025 with an April 6, 2026 lead‑plaintiff deadline — increases legal overhang and potential future liability. RARE Investor Alert: Kessler Topaz
• Negative Sentiment: Insider selling and institutional positioning: Recent filings highlighted insider sales (multiple officers) and mixed hedge fund moves (notable large reductions by some institutions) — potential signal of near‑term selling pressure or rebalancing. QuiverQuant summary (includes insider activity)
• Negative Sentiment: Pessimistic sell‑side note: Canaccord published a pessimistic forecast for RARE, adding downside analytical pressure amid mixed institutional flows and legal risk. Canaccord Genuity pessimistic forecast

Insider Buying and Selling at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 3,081 shares of the business’s stock in a transaction that occurred on Wednesday, December 10th. The stock was sold at an average price of $36.38, for a total value of $112,086.78. Following the sale, the chief financial officer owned 95,146 shares of the company’s stock, valued at $3,461,411.48. The trade was a 3.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Over the last three months, insiders have sold 6,227 shares of company stock worth $187,126. Company insiders own 5.50% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.